Webinars & Workshops
Wednesday, February 5, 2014 @ 12:00 pm – 1:30 pm EST
Unleash the potential of your DNA samples with an optimized target enrichment workflow for next-generation sequencing
Discover how the optimized target enrichment workflow from Roche NimbleGen and Kapa Biosystems enables improved performance in targeted resequencing.
In NGS target enrichment, researchers face challenges with low sample availability, sequencing of AT- or GC- skewed regions, or damaged DNA as in FFPE samples. By combining the SeqCap EZ products’ capture efficiency with Kapa’s expertise in library prep and high fidelity amplification, we have an effective solution for you to overcome these challenges.
During this webinar our R&D experts will share data demonstrating how our workflow will help you achieve greater molecular complexity with minimal DNA sample input or with FFPE DNA, hence maximizing variant discovery with your precious samples.
Daniel Burgess, PhD, Group Leader Sequence Capture
- Roche NimbleGen
Dr. Burgess holds a PhD degree from the Department of Human Genetics at the University of Michigan. He was a Postdoctoral Fellow and then Assistant Professor of Neurology at Baylor College of Medicine in Houston, Texas, where he published more than a dozen papers on ion channel genetics and function in epilepsy and other important neurologic disorders.
Dan joined Roche NimbleGen in 2008, where he currently leads efforts to develop cutting edge technologies for high resolution genome analysis. He has been a key contributor to the target enrichment product portfolio, including expansion of the SeqCap EZ product line from human exome to custom developed non-human products and collaborator designed gene panels.
Maryke Appel, PhD, Technical Director
- Kapa Biosystems
Dr. Appel received a PhD degree in Biochemistry from the University of Stellenbosch in South Africa in 2001. The focus of her post-graduate research was molecular plant-pathogen interactions. Prior to becoming Kapa's first employee in 2006, Dr Appel worked for a small biotech developing novel, targeted cancer therapeutics. At Kapa, she initially formed part of the Research & Development team. She participated in establishing Kapa's technology platform, and was responsible for developing the KAPA2G and KAPA Blood product lines. Since 2008, Dr Appel has played a leading role in Technical Support and Operations at Kapa. She currently leads the technical team in efforts to overcome the challenges of NGS library preparation.
Discover more, sequence less using SeqCap EZ Library. Learn more from our workshops & webinars listed below.